{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:00Z","timestamp":1786998420232,"version":"build-2736575974"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["MU-SRF-RS-05\\u202FA\/67"],"award-info":[{"award-number":["MU-SRF-RS-05\\u202FA\/67"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["N42A650352"],"award-info":[{"award-number":["N42A650352"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","award":["RSA6080061"],"award-info":[{"award-number":["RSA6080061"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.yexmp.2025.104952","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:15:13Z","timestamp":1738041313000},"page":"104952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Role of A1 adenosine receptor in cardiovascular diseases: Bridging molecular mechanisms with therapeutic opportunities"],"prefix":"10.1016","volume":"141","author":[{"given":"Warisara","family":"Parichatikanond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratchanee","family":"Duangrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narawat","family":"Nuamnaichati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supachoke","family":"Mangmool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.yexmp.2025.104952_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11302-011-9274-3","article-title":"Partial adenosine A1 receptor agonists for cardiovascular therapies","volume":"8","author":"Albrecht-K\u00fcpper","year":"2012","journal-title":"Purinergic Signal"},{"issue":"11","key":"10.1016\/j.yexmp.2025.104952_bb0010","doi-asserted-by":"crossref","first-page":"9260","DOI":"10.3390\/ijms24119260","article-title":"Reversal of tau-dependent cognitive decay by blocking adenosine A1 receptors: comparison of transgenic mouse models with different levels of tauopathy","volume":"24","author":"Anglada-Huguet","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2025.104952_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102393","article-title":"Adenosine signaling as target in cardiovascular pharmacology","volume":"71","author":"Antonioli","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0008-6363(02)00738-1","article-title":"Effects of A1 adenosine receptor overexpression on normoxic and post-ischemic gene expression","volume":"57","author":"Ashton","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0025","first-page":"H1327","article-title":"Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs","volume":"264","author":"Auchampach","year":"1993","journal-title":"Am. J. Phys."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0030","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/acs.jmedchem.8b00047","article-title":"A structure-activity relationship study of bitopic N(6)-substituted adenosine derivatives as biased adenosine A1 receptor agonists","volume":"61","author":"Aurelio","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yexmp.2025.104952_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bcp.2015.11.013","article-title":"Quantification of adenosine A1 receptor biased agonism: implications for drug discovery","volume":"99","author":"Baltos","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1096\/fasebj.9.5.7896004","article-title":"Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes","volume":"9","author":"Belardinelli","year":"1995","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.yexmp.2025.104952_bb0045","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41418-023-01187-0","article-title":"Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions","volume":"30","author":"Bernardi","year":"2023","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/pr.113.008540","article-title":"The A3 adenosine receptor: history and perspectives","volume":"67","author":"Borea","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects?","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0060","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018048","article-title":"Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism","volume":"6","author":"Bott-Fl\u00fcgel","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/2191-219X-3-65","article-title":"Cardioprotective effects of adenosine within the border and remote areas of myocardial infarction","volume":"3","author":"Bousquenaud","year":"2013","journal-title":"EJNMMI Res."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0075","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/ijms19030784","article-title":"The inside story of adenosine","volume":"19","author":"Camici","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2025.104952_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724320","article-title":"Pharmacological tuning of adenosine signal nuances underlying heart failure with preserved ejection fraction","volume":"12","author":"Campos-Martins","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"25","key":"10.1016\/j.yexmp.2025.104952_bb0085","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2174\/1381612825666190717105834","article-title":"Therapeutic potentials of A2B adenosine receptor ligands: current status and perspective","volume":"25","author":"Chandrasekaran","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1527-3466.2003.tb00122.x","article-title":"CVT-510: a selective A1 adenosine receptor agonist","volume":"21","author":"Cheung","year":"2003","journal-title":"Cardiovasc. Drug Rev."},{"issue":"10","key":"10.1016\/j.yexmp.2025.104952_bb0095","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/1440-1681.12616","article-title":"VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model","volume":"43","author":"Chuo","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1527-3466.2000.tb00043.x","article-title":"AMP579, a novel adenosine agonist for the treatment of acute myocardial infarction","volume":"18","author":"Clark","year":"2000","journal-title":"Cardiovasc. Drug Rev."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bph.14870","article-title":"The effect of two selective A1-receptor agonists and the bitopic ligand VCP746 on heart rate and regional vascular conductance in conscious rats","volume":"177","author":"Cooper","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bcp.2003.09.015","article-title":"2-ClATP exerts anti-tumoural actions not mediated by P2 receptors in neuronal and glial cell lines","volume":"67","author":"D\u2019Ambrosi","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.yexmp.2025.104952_bb0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.yexmp.2025.104952_bb0120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.RES.86.9.989","article-title":"Adenosine A1 receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism","volume":"86","author":"Dana","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.yexmp.2025.104952_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.856747","article-title":"Adenosine in acute myocardial infarction-associated reperfusion injury: does it still have a role?","volume":"13","author":"De Marco","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.104952_bb0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/164_2016_83","article-title":"Partial adenosine A1 agonist in heart failure","volume":"243","author":"Dinh","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.yexmp.2025.104952_bb0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cardfail.2007.08.006","article-title":"The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment","volume":"13","author":"Dittrich","year":"2007","journal-title":"J. Card. Fail."},{"issue":"11","key":"10.1016\/j.yexmp.2025.104952_bb0140","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.3390\/ijms25115763","article-title":"Adenosine A3 receptor: from molecular signaling to therapeutic strategies for heart diseases","volume":"25","author":"Duangrat","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2025.104952_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-pharmtox-061008-103038","article-title":"The role of G\u03b2\u03b3 subunits in the organization, assembly, and function of GPCR signaling complexes","volume":"49","author":"Dupr\u00e9","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"24","key":"10.1016\/j.yexmp.2025.104952_bb0150","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1161\/CIRCULATIONAHA.104.510982","article-title":"Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson","volume":"111","author":"Ellenbogen","year":"2005","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.yexmp.2025.104952_bb0155","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1161\/CIRCULATIONAHA.106.620211","article-title":"Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function","volume":"114","author":"Funakoshi","year":"2006","journal-title":"Circulation"},{"issue":"1\u20132","key":"10.1016\/j.yexmp.2025.104952_bb0160","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ddr.1143","article-title":"Negative chronotropic effect of CVT-510 in anesthetized and awake rats","volume":"52","author":"Gao","year":"2001","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.yjmcc.2005.06.001","article-title":"Adenosine triggers preconditioning through MEK\/ERK1\/2 signalling pathway during hypoxia\/reoxygenation in neonatal rat cardiomyocytes","volume":"39","author":"Germack","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0170","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.yjmcc.2004.08.001","article-title":"Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes","volume":"37","author":"Germack","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1\u20132","key":"10.1016\/j.yexmp.2025.104952_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11010-014-2312-z","article-title":"Remote ischemic preconditioning for myocardial protection: update on mechanisms and clinical relevance","volume":"402","author":"Gill","year":"2015","journal-title":"Mol. Cell. Biochem."},{"issue":"16","key":"10.1016\/j.yexmp.2025.104952_bb0180","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2007.07.019","article-title":"The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance","volume":"50","author":"Givertz","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.yexmp.2025.104952_bb0185","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/01.CIR.99.8.1034","article-title":"Electrophysiologic effects of adenosine in patients with supraventricular tachycardia","volume":"99","author":"Glatter","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0735-1097(99)00532-X","article-title":"Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure","volume":"35","author":"Gottlieb","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.yexmp.2025.104952_bb0195","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jacc.2007.03.059","article-title":"Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study","volume":"50","author":"Greenberg","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10741-015-9522-7","article-title":"Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure","volume":"21","author":"Greene","year":"2016","journal-title":"Heart Fail. Rev."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0205","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/jcm9051366","article-title":"Adenosine and the cardiovascular system: the good and the bad","volume":"9","author":"Guieu","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0210","doi-asserted-by":"crossref","first-page":"H1690","DOI":"10.1152\/ajpheart.2000.279.4.H1690","article-title":"Cardioprotection by KATP channels in wild-type hearts and hearts overexpressing A1-adenosine receptors","volume":"279","author":"Headrick","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0215","doi-asserted-by":"crossref","first-page":"H1797","DOI":"10.1152\/ajpheart.00407.2003","article-title":"Acute adenosinergic cardioprotection in ischemic-reperfused hearts","volume":"285","author":"Headrick","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0220","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.06.002","article-title":"Cardiovascular adenosine receptors: expression, actions and interactions","volume":"140","author":"Headrick","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150021","article-title":"Pharmacology of the adenosine A3 receptor in the vasculature and essential hypertension","volume":"11","author":"Ho","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/152308604322899404","article-title":"Role of adenosine receptor activation in antioxidant enzyme regulation during ischemia-reperfusion in the isolated rat heart","volume":"6","author":"Hochhauser","year":"2004","journal-title":"Antioxid. Redox Signal."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10557-013-6500-y","article-title":"Caspase inhibition via A3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction","volume":"28","author":"Hussain","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0240","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/HYPERTENSIONAHA.117.10765","article-title":"Adenosine receptors influence hypertension in dahl salt-sensitive rats: dependence on receptor subtype, salt diet, and sex","volume":"72","author":"Jackson","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.yexmp.2025.104952_bb0245","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"7","key":"10.1016\/j.yexmp.2025.104952_bb0250","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bjp.0707319","article-title":"The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5\/6 nephrectomy without affecting blood pressure","volume":"151","author":"Kalk","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.104952_bib701","doi-asserted-by":"crossref","first-page":"105704","DOI":"10.1016\/j.biocel.2020.105704","article-title":"Cytochrome c phosphorylation: control of mitochondrial electron transport chain flux and apoptosis","volume":"121","author":"Kalpage","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0260","doi-asserted-by":"crossref","first-page":"H145","DOI":"10.1152\/ajpheart.01036.2002","article-title":"Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor","volume":"285","author":"Kirchhof","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0898-6568(01)00235-2","article-title":"Adenosine receptors: G protein-mediated signalling and the role of accessory proteins","volume":"14","author":"Klinger","year":"2002","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0270","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0002-8703(03)00172-8","volume":"146","author":"Kopecky","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.yexmp.2025.104952_bb0275","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fphar.2018.00310","article-title":"Adenosine receptor-mediated cardioprotection-current limitations and future directions","volume":"9","author":"Lasley","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcin.2014.02.009","article-title":"Adenosine: physiology, pharmacology, and clinical applications","volume":"7","author":"Layland","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0285","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/CIRCRESAHA.117.311849","article-title":"Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease","volume":"121","author":"Leong","year":"2017","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/107424840100600304","article-title":"Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans","volume":"6","author":"Lerman","year":"2001","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"Pt 2","key":"10.1016\/j.yexmp.2025.104952_bb0295","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1042\/bj3360337","article-title":"Protein kinase C-dependent activation of KATP channel enhances adenosine-induced cardioprotection","volume":"336","author":"Liang","year":"1998","journal-title":"Biochem. J."},{"issue":"8","key":"10.1016\/j.yexmp.2025.104952_bb0300","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.RES.0000094744.88220.62","article-title":"Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model","volume":"93","author":"Liao","year":"2003","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0305","doi-asserted-by":"crossref","first-page":"H29","DOI":"10.1152\/ajpheart.01031.2001","article-title":"Sites of action of adenosine in interorgan preconditioning of the heart","volume":"283","author":"Liem","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0310","doi-asserted-by":"crossref","first-page":"H97","DOI":"10.1152\/ajpheart.00956.2002","article-title":"Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK","volume":"285","author":"Liu","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"10","key":"10.1016\/j.yexmp.2025.104952_bb0315","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1006\/jmcc.1999.1026","article-title":"Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes","volume":"31","author":"Liu","year":"1999","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0320","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.yexmp.2025.104952_bb0325","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3390\/biomedicines10112963","article-title":"Adenosine and adenosine receptors: advances in atrial fibrillation","volume":"10","author":"Maille","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.yexmp.2025.104952_bb0330","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3389\/fphar.2018.01336","article-title":"Therapeutic targets for treatment of heart failure: focus on GRKs and \u03b2-arrestins affecting \u03b2AR signaling","volume":"9","author":"Mangmool","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.104952_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116175","article-title":"Stimulation of adenosine A1 receptor prevents oxidative injury in H9c2 cardiomyoblasts: role of G\u03b2\u03b3-mediated Akt and ERK1\/2 signaling","volume":"451","author":"Mangmool","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0340","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0008-6363(96)00128-9","article-title":"Adenosine-induced renal vasoconstriction in man","volume":"32","author":"Marraccini","year":"1996","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0345","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/BF02207285","article-title":"Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells","volume":"431","author":"Martynyuk","year":"1996","journal-title":"Pflugers Arch."},{"issue":"15","key":"10.1016\/j.yexmp.2025.104952_bb0350","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0355","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-5381.1996.tb15412.x","article-title":"Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo","volume":"118","author":"Matho\u00f4t","year":"1996","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0360","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000535901","article-title":"The prognostic impact of renal function decline during hospitalization for heart failure","volume":"49","author":"Mayer","year":"2024","journal-title":"Kidney Blood Press. Res."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1074248410396877","article-title":"Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?","volume":"17","author":"McIntosh","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.yexmp.2025.104952_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.109954","article-title":"Biased agonism at adenosine receptors","volume":"82","author":"McNeill","year":"2021","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0375","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/01.HYP.37.3.862","article-title":"Antiadrenergic effects of adenosine in pressure overload hypertrophy","volume":"37","author":"Meyer","year":"2001","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0380","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/jpet.112.200873","article-title":"INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats","volume":"344","author":"Mor","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0385","doi-asserted-by":"crossref","first-page":"H1071","DOI":"10.1152\/ajpheart.2000.279.3.H1071","article-title":"Transgenic overexpression of cardiac A1 adenosine receptors mimics ischemic preconditioning","volume":"279","author":"Morrison","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0390","doi-asserted-by":"crossref","first-page":"H437","DOI":"10.1152\/ajpheart.00723.2001","article-title":"Cardiac effects of adenosine in A2A receptor knockout hearts: uncovering A2B receptors","volume":"282","author":"Morrison","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0395","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0008-6363(01)00358-3","article-title":"Adenosine, adenosine receptors and myocardial protection: an updated overview","volume":"52","author":"Mubagwa","year":"2001","journal-title":"Cardiovasc. Res."},{"issue":"5 Pt 2","key":"10.1016\/j.yexmp.2025.104952_bb0400","first-page":"F783","article-title":"Effects of selective A1 receptor blockade on glomerular hemodynamics: involvement of renin-angiotensin system","volume":"267","author":"Munger","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.yexmp.2025.104952_bb0405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-540-89615-9_6","article-title":"Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology","volume":"193","author":"Mustafa","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0410","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/jmcc.2000.1282","article-title":"Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes","volume":"33","author":"Narayan","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0415","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcin.2013.02.009","volume":"6","author":"Niccoli","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0420","doi-asserted-by":"crossref","first-page":"H743","DOI":"10.1152\/ajpheart.00071.2018","article-title":"Adenosine A1 receptors and mitochondria: targets of remote ischemic preconditioning","volume":"316","author":"Paez","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0425","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1074\/jbc.272.2.754","article-title":"Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine","volume":"272","author":"Parkinson","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0430","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pharmthera.2007.02.004","article-title":"Adenosinergic cardioprotection: multiple receptors, multiple pathways","volume":"114","author":"Peart","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0435","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.crd.0000181621.84565.9d","article-title":"Tecadenoson: a novel, selective A1 adenosine receptor agonist","volume":"13","author":"Peterman","year":"2005","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.yexmp.2025.104952_bb0440","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fphar.2017.00428","article-title":"Stimulation of adenosine A2B receptor inhibits endothelin-1-induced cardiac fibroblast proliferation and \u03b1-smooth muscle actin synthesis through the cAMP\/Epac\/PI3K\/Akt-signaling pathway","volume":"8","author":"Phosri","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0445","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11302-017-9600-5","article-title":"Epac is required for exogenous and endogenous stimulation of adenosine A2B receptor for inhibition of angiotensin II-induced collagen synthesis and myofibroblast differentiation","volume":"14","author":"Phosri","year":"2018","journal-title":"Purinergic Signal"},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0450","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0735-1097(03)00987-2","article-title":"Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist","volume":"42","author":"Prystowsky","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0455","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bph.13339","article-title":"Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to \u03b11 -adrenoceptor stimulation in vivo","volume":"173","author":"Puhl","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0460","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/6165","article-title":"Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice","volume":"17","author":"Redfern","year":"1999","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.yexmp.2025.104952_bb0465","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1073\/pnas.97.9.4826","article-title":"Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy","volume":"97","author":"Redfern","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0470","doi-asserted-by":"crossref","first-page":"H859","DOI":"10.1152\/ajpheart.00251.2002","article-title":"A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity","volume":"284","author":"Regan","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0475","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.RES.0000156075.00127.C3","article-title":"Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance","volume":"96","author":"Reichelt","year":"2005","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0480","doi-asserted-by":"crossref","first-page":"H2253","DOI":"10.1152\/ajpheart.01009.2004","article-title":"In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling","volume":"288","author":"Reid","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0485","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40256-019-00345-5","article-title":"Adenosine and the cardiovascular system","volume":"19","author":"Reiss","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"19","key":"10.1016\/j.yexmp.2025.104952_bb0490","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.3390\/ijms21197412","article-title":"p38 MAPK pathway in the heart: new insights in health and disease","volume":"21","author":"Romero-Becerra","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2025.104952_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628060","article-title":"Pharmacological insights into safety and efficacy determinants for the development of adenosine receptor biased agonists in the treatment of heart failure","volume":"12","author":"Rueda","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0500","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.112.000208","article-title":"Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure","volume":"6","author":"Sabbah","year":"2013","journal-title":"Circ. Heart Fail."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0505","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-201X.2004.01350.x","article-title":"Adenosine A1 receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia","volume":"182","author":"Schulte","year":"2004","journal-title":"Acta Physiol. Scand."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0510","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1139\/y06-007","article-title":"Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase","volume":"84","author":"Sch\u00fctte","year":"2006","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"9","key":"10.1016\/j.yexmp.2025.104952_bb0515","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3390\/ijms21093167","article-title":"Ischemic heart disease and heart failure: role of coronary ion channels","volume":"21","author":"Severino","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0520","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CRD.0b013e31819f1a98","article-title":"Adenosine1 receptor antagonism: a new therapeutic approach for the treatment of decompensated heart failure","volume":"17","author":"Shah","year":"2009","journal-title":"Cardiol. Rev."},{"issue":"21","key":"10.1016\/j.yexmp.2025.104952_bb0525","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/jama.2019.6717","article-title":"Effect of neladenoson bialanate on exercise capacity among patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"321","author":"Shah","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0530","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: expression, function and regulation","volume":"15","author":"Sheth","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0535","doi-asserted-by":"crossref","first-page":"H441","DOI":"10.1152\/ajpheart.00589.2005","article-title":"Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt","volume":"290","author":"Solenkova","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0540","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1159\/000493037","article-title":"PI3K-AKT pathway protects cardiomyocytes against hypoxia-induced apoptosis by mitoKATP-mediated mitochondrial translocation of pAKT","volume":"49","author":"Song","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0545","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0163-7258(01)00152-8","article-title":"Pharmacology of adenosine receptors in the vasculature","volume":"91","author":"Tabrizchi","year":"2001","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.yexmp.2025.104952_bb0550","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.3390\/ijms24054404","article-title":"Expression and impact of adenosine A3 receptors on calcium homeostasis in human right atrium","volume":"24","author":"Tarifa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0555","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/11594680-000000000-00000","article-title":"The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT","volume":"35","author":"Teerlink","year":"2012","journal-title":"Drug Saf."},{"issue":"7","key":"10.1016\/j.yexmp.2025.104952_bb0560","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00392-012-0430-8","article-title":"The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina","volume":"101","author":"Tendera","year":"2012","journal-title":"Clin. Res. Cardiol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.104952_bb0565","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1073\/pnas.1320962111","article-title":"Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist","volume":"111","author":"Valant","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0570","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.yexmp.2025.104952_bb0575","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejheart.2008.01.010","article-title":"Adenosine and kidney function: potential implications in patients with heart failure","volume":"10","author":"Vallon","year":"2008","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0580","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ejhf.1320","article-title":"Treating oxidative stress in heart failure: past, present and future","volume":"21","author":"Van der Pol","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.yexmp.2025.104952_bb0585","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2016.08.007","article-title":"The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling","volume":"117","author":"Vecchio","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.104952_bb0590","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fphar.2017.00243","article-title":"Targeting adenosine receptors for the treatment of cardiac fibrosis","volume":"8","author":"Vecchio","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.104952_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.625134","article-title":"A1 adenosine receptor partial agonists and allosteric modulators: advancing toward the clinic?","volume":"11","author":"Vincenzi","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.yexmp.2025.104952_bb0600","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/biom13091387","article-title":"Pharmacology of adenosine receptors: recent advancements","volume":"13","author":"Vincenzi","year":"2023","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.yexmp.2025.104952_bb0605","article-title":"Decreased renal function is associated with heart failure readmissions","volume":"10","author":"Vindhyal","year":"2018","journal-title":"Cureus"},{"issue":"19","key":"10.1016\/j.yexmp.2025.104952_bb0610","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jacc.2010.11.057","volume":"57","author":"Voors","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0615","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jcph.828","article-title":"Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure","volume":"57","author":"Voors","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.yexmp.2025.104952_bb0620","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/ejhf.1295","article-title":"Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction","volume":"20","author":"Voors","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.yexmp.2025.104952_bb0625","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/ejhf.1591","article-title":"Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial","volume":"21","author":"Voors","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"9","key":"10.1016\/j.yexmp.2025.104952_bb0630","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/cells11091553","article-title":"Insight into the role of the PI3K\/Akt pathway in ischemic injury and post-infarct left ventricular remodeling in normal and diabetic heart","volume":"11","author":"Walkowski","year":"2022","journal-title":"Cells"},{"issue":"2 Pt 2","key":"10.1016\/j.yexmp.2025.104952_bb0640","first-page":"F227","article-title":"Synergistic effects of angiotensin and adenosine in the renal microvasculature","volume":"266","author":"Weihprecht","year":"1994","journal-title":"Am. J. Phys."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0645","doi-asserted-by":"crossref","first-page":"H2161","DOI":"10.1152\/ajpheart.00639.2010","article-title":"Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning","volume":"300","author":"Williams-Pritchard","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0650","doi-asserted-by":"crossref","first-page":"H334","DOI":"10.1152\/ajpheart.2001.280.1.H334","article-title":"A partial agonist of the A1-adenosine receptor selectively slows AV conduction in guinea pig hearts","volume":"280","author":"Wu","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.104952_bb0655","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/jpet.106.110494","article-title":"Distinct KATP channels mediate the antihypertrophic effects of adenosine receptor activation in neonatal rat ventricular myocytes","volume":"320","author":"Xia","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0660","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1440-1681.2009.05300.x","article-title":"Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes","volume":"37","author":"Xiang","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.104952_bb0665","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1006\/jmcc.2000.1264","article-title":"Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion","volume":"32","author":"Xu","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.yexmp.2025.104952_bb0670","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cardiores.2004.12.004","article-title":"Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes","volume":"65","author":"Xu","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yexmp.2025.104952_bb0675","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.723332","article-title":"Remote conditioning by rhythmic compression of limbs ameliorated myocardial infarction by downregulation of inflammation via A2 adenosine receptors","volume":"8","author":"Xu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"12","key":"10.1016\/j.yexmp.2025.104952_bb0680","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1248\/bpb.17.1599","article-title":"Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in anesthetized dogs","volume":"17","author":"Yamagata","year":"1994","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0685","doi-asserted-by":"crossref","first-page":"H949","DOI":"10.1152\/ajpheart.00741.2001","article-title":"Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction","volume":"282","author":"Yang","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.104952_bb0690","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.yjmcc.2003.12.008","article-title":"NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO","volume":"36","author":"Yang","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.104952_bb0695","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10557-004-6220-4","article-title":"The p38 MAPK inhibitor SB203580 blocks adenosine A1 receptor-induced attenuation of in vivo myocardial stunning","volume":"18","author":"Yoshimura","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"9","key":"10.1016\/j.yexmp.2025.104952_bb0700","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J. Clin. Invest."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480025000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480025000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:22:44Z","timestamp":1777404164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480025000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":140,"alternative-id":["S0014480025000012"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2025.104952","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of A1 adenosine receptor in cardiovascular diseases: Bridging molecular mechanisms with therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2025.104952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104952"}}